art2Fcc986.pdf (384.05 kB)
Superantigen antagonist peptides
journal contribution
posted on 2023-06-21, 06:01 authored by Martin LlewelynMartin Llewelyn, Jonathan CohenThe production of superantigenic exotoxins by Gram positive bacteria underlies the pathology of toxic shock syndrome. Future treatment strategies for superantigen-mediated diseases are likely to be directed at blocking the three-way interaction between superantigen, T cell receptor and major histocompatibility class II molecule, which inititates an excessive and disordered inflammatory response. In this article, we review the first published data to address one such strategy in the context of other recognised and experimental treatments.
History
Publication status
- Published
File Version
- Published version
Journal
Critical CareISSN
1364-8535Publisher
BioMed CentralExternal DOI
Volume
5Page range
53-55Department affiliated with
- Global Health and Infection Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2016-10-03First Open Access (FOA) Date
2016-10-03First Compliant Deposit (FCD) Date
2016-10-03Usage metrics
Categories
No categories selectedKeywords
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC